KNSA
NMS 股策精挑入选日 2026-07-11 · 入选 47 天基本信息
成交结构
基于近 60 日量价数据观察资金强弱。
交易信号历史
按时间回看该股票被模型捕捉到的买点信号。
| 信号日期 | 模型来源 | 评分/强度 | 信号价格 | 止损价 | 止盈价 | 当前表现 | 操作结论 |
|---|---|---|---|---|---|---|---|
| 2026-07-16 | 动量强势 | +28.5% | $61.69 | $59.22 | $66.63 | +30.6% | 可买入 |
| 2026-07-14 | 综合评分 | 75 | $60.94 | $55.10 | $72.63 | +32.2% | 可买入 |
| 2026-07-14 | 股策精挑 | 74 | $60.94 | $56.06 | $70.69 | +32.2% | 可买入 |
| 2026-07-13 | 股策精挑 | 62 | $63.44 | $58.36 | $73.59 | +27.0% | 可买入 |
公司简介
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
最新资讯
